NASDAQ:ARQT

Arcutis Biotherapeutics Stock News

Healthcare > Biotechnology

Buy ARQT

*Your capital is at risk

$26.27

-0.390 (-1.46%)

At Close: Jun 23, 2026

The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

12:23pm, Tuesday, 11'th Feb 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN )

The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

12:43pm, Wednesday, 05'th Feb 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (N

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

09:05pm, Tuesday, 04'th Feb 2020

WESTLAKE VILLAGE, Calif., Feb. 04, 2020 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by